These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Wojtkowiak-Szlachcic A, Taylor K, Stepniak-Konieczna E, Sznajder LJ, Mykowska A, Sroka J, Thornton CA, Sobczak K. Nucleic Acids Res; 2015 Mar 31; 43(6):3318-31. PubMed ID: 25753670 [Abstract] [Full Text] [Related]
3. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy. Christou M, Wengel J, Sokratous K, Kyriacou K, Nikolaou G, Phylactou LA, Mastroyiannopoulos NP. Nucleic Acid Ther; 2020 Apr 31; 30(2):80-93. PubMed ID: 31873063 [Abstract] [Full Text] [Related]
8. Loss of MBNL1-mediated retrograde BDNF signaling in the myotonic dystrophy brain. Wang PY, Kuo TY, Wang LH, Liang WH, Wang GS. Acta Neuropathol Commun; 2023 Mar 15; 11(1):44. PubMed ID: 36922901 [Abstract] [Full Text] [Related]
16. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models. González ÀL, Konieczny P, Llamusi B, Delgado-Pinar E, Borrell JI, Teixidó J, García-España E, Pérez-Alonso M, Estrada-Tejedor R, Artero R. PLoS One; 2017 Jun 15; 12(6):e0178931. PubMed ID: 28582438 [Abstract] [Full Text] [Related]